Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/04/2026 BST			5-day change	1st Jan Change
7.270 ^USD	-0.68%		-0.27%	-17.57%

04-13	Geron Corporation Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary	CI
04-09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT

Vanda Pharmaceuticals Inc. Reiterates Revenue Guidance for the Full Year 2025

Published on 05/07/2025 at 09:01 pm BST

S&P Capital IQ

VANDA PHARMACEUTICALS INC.

-0.68%

Vanda Pharmaceuticals Inc. reiterated revenue guidance for the full year 2025. For the year, the company expects total revenue of $210 million- $250 million.

Latest news about Vanda Pharmaceuticals Inc.

04-13	Geron Corporation Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary	CI
04-09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT
04-08	Vanda Pharmaceuticals Starts Study of Nereus to Address GLP-1 Side Effects	MT
04-08	Vanda Pharmaceuticals announces initiation of the Thetis study, a clinical trial of Nereus(TM) for the prevention of vomiting induced by GLP-1 receptor agonists	RE
04-08	Vanda Pharmaceuticals Inc. Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS? for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	CI
04-02	Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026	CI
03-30	FDA Issues Final Decision on Vanda Pharmaceuticals? Hearing Request for Tradipitant NDA	CI
03-27	AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares	MT
03-27	EMA's CHMP recommends extension of therapeutic indication for Pfizer's Hympavzi	RE
03-23	Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to S&P Biotechnology Select Industry Index	CI
03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT
03-03	Vanda Pharmaceuticals Inc. Announces FDA Grants Landmark Hearing for HETLIOZin Jet Lag Disorder	CI
03-03	Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years	RE
03-03	Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag	MT

Chart Vanda Pharmaceuticals Inc.

Duration

Period

VNDA: Dynamic Chart

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâ€™s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

533

Sector

Biotechnology & Medical Research

More about the company